BRAF and neoplasm: Thus, it has been suggested that a preoperative “neoadjuvant” therapy with a BRAF-directed therapy or, in case of BRAF non-mutated tumors, a mKI/checkpoint inhibitor combination can lead to tumor resectability in locally advanced ATC and optimize local tumor control.